Quick Answer
Contineum Therapeutics, Inc. reported Earnings Per Share Diluted of $2.17 (loss) per share for the year ending 2025.
- Contineum Therapeutics, Inc. showed an increase of +0.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Contineum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $0.84 per share | Q3 2023: $2.69 (loss) per share | Q2 2024: $0.39 (loss) per share | Q3 2024: $0.40 (loss) per share.
- Over the full 3 years of available data (2023 to 2025), Contineum Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 2,812.5%.
- Historical annual values: Fiscal year 2025: $2.17 (loss) per share | Fiscal year 2024: $2.18 (loss) per share | Fiscal year 2023: $0.08 per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: